BioCryst is profitable. Now it wants to buy more rare disease drugs
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
BioCryst is profitable. Now it wants to buy more rare disease drugs basliginda one cikan gelisme: Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.